.jpg)
Compounds for the treatment of canine Leishmaniosis
Patent number:
P202230181
No items found.
New family of compounds with demonstrated in vitro efficacy against intracellular parasites responsible for leishmaniasis and American trypanosomiasis or Chagas disease. Pharmacokinetic and toxicity studies have been conducted in rats, as well as preliminary efficacy studies in a murine model.
Countries:
Spain
Regions:
Community of Madrid
Centers:
CSIC
Other entities:
Sectors:
Food & Agro
Subsectors:
Pharmaceuticals
TRL Level:
TRL 4 – technology validated in lab
BRL Level:
PDF Link:
Download hereVideo Link:
Watch it hereSustainable Development Goal:
Applications
Los compuestos desarrollados han demostrado 100% de eficacia in vitro sobre parásitos causantes de leishmaniosis. El índice terapéutico (in vitro) hacía estos parásitos es alto (> 76 contra Leishmania, > 69 contra T. cruzi). Se han obtenido datos prometedores en ensayos de eficacia in vivo en modelo murino de Leishmaniosis visceral mediante administración oral del compuesto líder.
Comments